Recipharm Signs Memorandum of Understanding (MOU) for the Fill Finish of Vaccines & Biotherapeutics in Morocco
Global contract development and manufacturing organization (CDMO) Recipharm has recently signed an MOU, along with His Majesty the King of Morocco, Mohammed VI, the Moroccan Government and a consortium of the country’s leading banks, that will see the company operate a new fill finish factory in Morocco.
As part of the MOU around $500 million will be invested by the Moroccan Government and consortium over the next 5 years to establish both capacity and capability for the manufacturing of vaccines and biotherapeutics in Morocco. The investment is primarily to supply the African continent and help it gain vaccine sovereignty and access to future biotherapeutics.
The factory, which will be located on a 42 hectare greenfield site is planned to be operational by 2023, will be run by Recipharm and will mirror the company’s new fill finish line at its facility in Monts, France, on a larger scale.
Marc Funk, CEO of Recipharm, said “It’s an honor to act as the CDMO of choice on this project. Together with the other parties involved, we will be able to work to offer Africa a concrete opportunity to gradually gain health independence from western countries and ultimately help to ensure it is less vulnerable in times of crisis. Our expertise and previous experience of fill finish manufacturing means we’re ideally placed to ensure successful tech transfer and high-quality operations.”
Recipharm is a leading Contract Development and Manufacturing Organization (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. For more information, visit www.recipharm.com.
Total Page Views: 403